Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Share-based Compensation (2020 - 2025)

Legend Biotech filings provide 6 years of Share-based Compensation readings, the most recent being $15.0 million for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 0.64% to $15.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $64.8 million, a 4.65% decrease, with the full-year FY2022 number at $34.3 million, up 70.34% from a year prior.
  • Share-based Compensation hit $15.0 million in Q3 2025 for Legend Biotech, down from $18.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $34.3 million in Q4 2022 to a low of $2.3 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $15.1 million (2024), compared with a mean of $14.8 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 323.49% in 2021 and later decreased 14.74% in 2025.
  • Legend Biotech's Share-based Compensation stood at $20.2 million in 2021, then skyrocketed by 70.34% to $34.3 million in 2022, then plummeted by 63.96% to $12.4 million in 2023, then rose by 22.09% to $15.1 million in 2024, then fell by 0.64% to $15.0 million in 2025.
  • The last three reported values for Share-based Compensation were $15.0 million (Q3 2025), $18.7 million (Q2 2025), and $15.9 million (Q1 2025) per Business Quant data.